Accessibility Menu
Livzon Pharmaceutical Group logo

Livzon Pharmaceutical Group(SEHK) 1513

Market CapHK$18.02BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)+89%
5 Year-34%
1 Year-44%
1 Month-23%
HK$19.88
-2.07%
-0.42Today
Livzon Pharmaceutical Group last closing stock price
MetricPriceDate
Last closeHKD 19.882026-08-31
Livzon Pharmaceutical Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.33%HKD 21.002026-08-24
1 month-23.42%HKD 25.962026-07-31
3 month-25.6%HKD 26.722026-06-02
Year to date-30.29%HKD 28.522025-12-31
1 year-43.91%HKD 35.442025-08-29
3 year-20%HKD 24.852023-08-31
5 year-33.73%HKD 30.002021-09-01
Since inception+88.68%HKD 10.762014-01-16

Livzon Pharmaceutical Group Financials at a Glance

Market Cap

HK$18.02BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥10.70B

Net Income (TTM)

CN¥1.67B

EPS (TTM)

HK$2.11

P/E Ratio

9.61

Dividend

HK$1.64

Beta (Volatility)

-0.04 (Low)

Price

HK$19.88

Volume

1,217,000

Open

HK$20.30

Previous Close

HK$20.30

Daily Range

HK$19.80 - HK$20.30

52-Week Range

HK$19.80 - HK$38.78

Estimated Earnings Date

Oct 27, 2026

1513 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Livzon Pharmaceutical Group

Livzon Pharmaceutical Group Inc. is a leading pharmaceutical enterprise based in Zhuhai, China, established in 1985. The company specializes in the research, development, manufacturing, and global commercialization of a diverse range of pharmaceutical products, including finished drugs and active pharmaceutical ingredients.

Products and Services
  • Specialized medications for various conditions, including ulcers and schizophrenia
  • Diagnostic reagents and kits for infectious diseases and autoimmune disorders
  • Comprehensive product line including antibiotics and traditional Chinese medicines
Growth Outlook
  • Strong revenue growth with Q1 2026 revenue reaching CNY 2.87 billion
  • Continued investment in R&D, with expenses of CNY 169 million in Q1 2026
  • Expansion into international markets, enhancing global presence and sales
Financial Highlights
  • Net income of CNY 577 million in Q1 2026, reflecting a 200% increase year-over-year
  • Gross profit margin of 65.9% in Q1 2026, indicating strong operational efficiency
  • Dividend yield of 4.67% TTM, providing attractive returns to shareholders
Livzon Pharmaceutical Group Inc. has established itself as a significant player in the pharmaceutical industry, with a robust portfolio of products that cater to various medical needs. The company's commitment to research and development is evident in its substantial investment in R&D, which positions it well for future growth. Recent financial performance highlights a strong upward trend, particularly in net income and gross profit margins, showcasing operational efficiency and profitability. The attractive dividend yield further enhances the investment appeal, making Livzon a noteworthy consideration for potential investors interested in the healthcare sector.
AI Generated • Aug 20, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

8,878

CEO

Huan Guang Han, MBA

Website

www.livzon.com.cn

Headquarters

Zhuhai, GD 519090, CN

1513 Financials

Key Financial Metrics (TTM)

Gross Margin

62.84%

Operating Margin

20.23%

Net Income Margin

15.58%

Return on Equity

11.97%

Return on Capital

16.61%

Return on Assets

7.10%

Earnings Yield

10.41%

Dividend Yield

8.09%

Payout Ratio

1.36%

Stock Overview

Market Cap

HK$18.02BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

887.91M

Volume

1.22M

Avg. Volume

1.08M

Financials (TTM)

Gross Profit

CN¥6.72B

Operating Income

CN¥2.20B

EBITDA

CN¥2.70B

Operating Cash Flow

CN¥3.30B

Capital Expenditure

-CN¥397.62M

Free Cash Flow

CN¥2.90B

Cash & ST Invst.

CN¥8.19B

Total Debt

CN¥4.24B

Livzon Pharmaceutical Group Performance Analysis

Livzon Pharmaceutical Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 14,559,449,6811.0%
20232023-12-31CNY 13,612,724,868-6.5%
20242024-12-31CNY 12,700,649,035-6.7%
20252025-12-31CNY 12,915,975,1661.7%
Livzon Pharmaceutical Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-8.0%
Q42025-12-310.7%
Q12026-03-310.3%
Q22026-06-30-26.2%
Livzon Pharmaceutical Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 2.373.6%
20232023-12-31CNY 2.32-2.2%
20242024-12-31CNY 2.434.7%
20252025-12-31CNY 2.461.2%
Livzon Pharmaceutical Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-25.0%
Q42025-12-31-44.4%
Q12026-03-31116.7%
Q22026-06-30-38.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥2.12B

-31.4%

Gross Profit

CN¥1.12B

-45.9%

Gross Margin

52.93%

N/A

Market Cap

HK$18.02BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$2.03M

N/A

Employees

8,878

N/A

Net Income

CN¥353.78M

-45.1%

EBITDA

CN¥549.88M

-37.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥8.19B

-22.8%

Total Debt

CN¥4.24B

+20.6%

Accounts Receivable

CN¥2.78B

-20.4%

Inventory

CN¥1.80B

+4.8%

Long Term Debt

CN¥44.38M

-96.8%

Short Term Debt

CN¥4.19B

+96.8%

Return on Assets

7.10%

N/A

Return on Invested Capital

14.37%

N/A

Free Cash Flow

CN¥864.74M

+21.0%

Operating Cash Flow

CN¥980.59M

+1.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About 1513

What is the current price of Livzon Pharmaceutical Group?

Livzon Pharmaceutical Group is trading at HK$19.88 per share.

What is the 52-week range for Livzon Pharmaceutical Group?

Over the past 52 weeks, Livzon Pharmaceutical Group has traded between HK$19.80 and HK$38.78.

How much debt does Livzon Pharmaceutical Group have?

As of the most recent reporting period, Livzon Pharmaceutical Group reported total debt of CN¥4.90B.

How much cash does Livzon Pharmaceutical Group have on hand?

Livzon Pharmaceutical Group reported CN¥8.60B in cash and cash equivalents in its most recent financial results.

What is Livzon Pharmaceutical Group’s dividend yield?

Livzon Pharmaceutical Group currently has a dividend yield of 8.09%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services